Cargando…
If Not Now, When? Nonserotype Pneumococcal Protein Vaccines
The sudden emergence and global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have greatly accelerated the adoption of novel vaccine strategies, which otherwise would have likely languished for years. In this light, vaccines for certain other pathogens could certainly benefi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684483/ https://www.ncbi.nlm.nih.gov/pubmed/34934775 http://dx.doi.org/10.1093/ofid/ofab576 |
_version_ | 1784617628781772800 |
---|---|
author | McDaniel, Larry S Swiatlo, Edwin |
author_facet | McDaniel, Larry S Swiatlo, Edwin |
author_sort | McDaniel, Larry S |
collection | PubMed |
description | The sudden emergence and global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have greatly accelerated the adoption of novel vaccine strategies, which otherwise would have likely languished for years. In this light, vaccines for certain other pathogens could certainly benefit from reconsideration. One such pathogen is Streptococcus pneumoniae (pneumococcus), an encapsulated bacterium that can express >100 antigenically distinct serotypes. Current pneumococcal vaccines are based exclusively on capsular polysaccharide—either purified alone or conjugated to protein. Since the introduction of conjugate vaccines, the valence of pneumococcal vaccines has steadily increased, as has the associated complexity and cost of production. There are many pneumococcal proteins invariantly expressed across all serotypes, which have been shown to induce robust immune responses in animal models. These proteins could be readily produced using recombinant DNA technology or by mRNA technology currently used in SARS-CoV-2 vaccines. A door may be opening to new opportunities in affordable and broadly protective vaccines. |
format | Online Article Text |
id | pubmed-8684483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86844832021-12-20 If Not Now, When? Nonserotype Pneumococcal Protein Vaccines McDaniel, Larry S Swiatlo, Edwin Open Forum Infect Dis Perspectives The sudden emergence and global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have greatly accelerated the adoption of novel vaccine strategies, which otherwise would have likely languished for years. In this light, vaccines for certain other pathogens could certainly benefit from reconsideration. One such pathogen is Streptococcus pneumoniae (pneumococcus), an encapsulated bacterium that can express >100 antigenically distinct serotypes. Current pneumococcal vaccines are based exclusively on capsular polysaccharide—either purified alone or conjugated to protein. Since the introduction of conjugate vaccines, the valence of pneumococcal vaccines has steadily increased, as has the associated complexity and cost of production. There are many pneumococcal proteins invariantly expressed across all serotypes, which have been shown to induce robust immune responses in animal models. These proteins could be readily produced using recombinant DNA technology or by mRNA technology currently used in SARS-CoV-2 vaccines. A door may be opening to new opportunities in affordable and broadly protective vaccines. Oxford University Press 2021-12-18 /pmc/articles/PMC8684483/ /pubmed/34934775 http://dx.doi.org/10.1093/ofid/ofab576 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Perspectives McDaniel, Larry S Swiatlo, Edwin If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title | If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title_full | If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title_fullStr | If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title_full_unstemmed | If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title_short | If Not Now, When? Nonserotype Pneumococcal Protein Vaccines |
title_sort | if not now, when? nonserotype pneumococcal protein vaccines |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8684483/ https://www.ncbi.nlm.nih.gov/pubmed/34934775 http://dx.doi.org/10.1093/ofid/ofab576 |
work_keys_str_mv | AT mcdaniellarrys ifnotnowwhennonserotypepneumococcalproteinvaccines AT swiatloedwin ifnotnowwhennonserotypepneumococcalproteinvaccines |